Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Mulhouse – page 28

713 clinical trials in Mulhouse, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Mulhouse at a glance
713
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

713 trials in Mulhouse

Open in trial search

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Takeda Development Center Americas Inc.

Non-small cell lung cancer

Not yet recruiting

Safety and efficacy of rilvegostomig with drug combination in adult patients with unresectable stage III non‑small cell lung cancer undergoing chemoradiotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Interstitial lung disease+1

Not yet recruiting

A Phase 2 Study Evaluating the Safety and Efficacy of Oral NS-863 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:NS-863
  • Sponsor:Ns Pharma Inc.

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Phase 2 study of lutetium (177Lu) vipivotide tetraxetan with ADT and darolutamide in patients with metastatic hormone‑sensitive prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:Medical Center - University Of Freiburg

Pneumonia+1

Not yet recruiting

Early Use of Dexamethasone versus Sodium Chloride Placebo in Patients with Severe Influenza-Induced Acute Hypoxemic Respiratory Failure (Phase III Randomized Trial)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospital Region Metz Thionville

Metastatic malignant melanoma+2

Not yet recruiting

Methoxsalen (ECP) versus drug combination for steroid‑refractory immune‑related colitis or hepatitis in metastatic melanoma on checkpoint therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Therakos Europe Limited

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Septic shock

Not yet recruiting

Efficacy of dapagliflozin in adult patients with septic shock and microcirculatory dysfunction

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:French Innovative Leukemia Organization

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Mulhouse

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple myeloma, lung cancer, and colorectal cancer treatments, evaluating novel therapeutic combinations and immunotherapy approaches.

  • Multiple Myeloma Treatment Innovation
  • Advanced NSCLC Therapies
  • Metastatic Cancer Management

Clinical trials investigating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Autoimmune Conditions

Studies examining treatments for Sjögren's Syndrome and Systemic Lupus Erythematosus, with emphasis on innovative therapeutic approaches.

  • Novel Biologics Development
  • Disease Activity Management
  • Long-term Safety Studies

Research focused on improving quality of life for patients with chronic autoimmune conditions.

03 Respiratory Medicine

Investigating treatments for COPD and pulmonary infections, including studies on inhalation therapies and antimicrobial treatments.

  • COPD Management
  • Pulmonary Infection Treatment
  • Respiratory Drug Delivery

Clinical research aimed at enhancing respiratory health outcomes through innovative therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.